

## Publicaties ROW

### Journal articles

Per 1 september 2025

Al-Samkari H, Kasthuri RS, Mager HJ, Zhou JY, Serra MM, Samuelson-Bannow BT, Van Doren LN, Piccirillo JF, Clancy MS, McCrae KR, Thomas SM, Riera-Mestre A, Pishko AM, Sewaralthahab S, Gossage JR, Iyer VN, Hermans C, Hammill A, Winship I, Mei-Zahav M, von Drygalski A, Olitsky S, Faughnan ME. Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report.. *American journal of hematology* 2025; [Epub ahead of print].

Hessels J, Klompmaker S, van den Heuvel DAF, Boerman S, Mager JJ, Post MC. Graded transthoracic contrast echocardiography after pulmonary arteriovenous malformation embolization: can chest CT be avoided in patients with a low grade shunt?. *Chest* 2025; 167(3): 842-850.

Hessels J, Post MC, Boerman S, Droege F, Dupuis O, Geisthoff UW, Haahr PD, Kjeldsen AD, Mager JJ, Dupuis-Girod S, Buscarini E. Family planning, sexual activity and contraception in hereditary hemorrhagic telangiectasia: a European survey study.. *Orphanet journal of rare diseases* 2025; 20(1): 395.

ten Berg F, Hessels J, Hosman A, Boerman S, Post MC, Balemans WAF, Mager HJ. Conservative Pulmonary Arteriovenous Malformation Screening in Children: Re-Evaluation of Safety.. *Pediatric pulmonology* 2025; 60(1): e27476.

Thalgott JH, Zucker N, Deffieux T, Koopman MS, Dizeux A, Avramut CM, Koning RI, Mager HJ, Rabelink TJ, Tanter M, Lebrin F. Non-invasive characterization of pericyte dysfunction in mouse brain using functional ultrasound localization microscopy.. *Nature biomedical engineering* 2025; [Epub ahead of print].

Hessels J, Kroon S, Vorselaars VVM, Boerman S, Mager JJ, Post MC. Evolution of pulmonary arteriovenous malformations: the role of contrast echocardiography.. *Chest* 2023; 163(3): 669-677.

Dupuis-Girod S, Shovlin CL, Kjeldsen AD, Mager HJ, Sabba C, Droege F, Fargeton AE, Fialla AD, Gandolfi S, Hermann R, Lenato GM, Manfredi G, Post MC, Rennie C, Suppressa P, Sure U, ePag group. European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?. *European journal of medical genetics* 2022; 65(10): Article 104575.

Hessels Josefien, Kroon Steven, Boerman Sanne, Nelissen Rik C, Grutters Jan C, Snijder Repke J, Lebrin Franck, Post Marco C, Mummery Christine L, Mager Johannes-Jurgen. Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study. *Journal of Clinical Medicine* 2022; 11(18): 5280.

Orlova VV, Nahon DM, Cochrane A, Cao X, Freund C, van den Hil F, Westermann CJJ, Snijder RJ, Ploos van Amstel JK, Ten Dijke P, Lebrin F, Mager HJ, Mummery CL. Vascular defects associated with

hereditary hemorrhagic telangiectasia revealed in patient-derived isogenic iPSCs in 3D vessels on chip.. *Stem cell reports* 2022; 17(7): 1536-1545.

Shovlin CL, Buscarini E, Sabbà C, Mager HJ, Kjeldsen AD, Pagella F, Sure U, Ugolini S, Toerring PM, Suppressa P, Rennie C, Post MC, Patel MC, Nielsen TH, Manfredi G, Lenato GM, Lefroy D, Kariholu U, Jones B, Fialla AD, Eker OF, Dupuis O, Droege F, Coote N, Boccardi E, Alsafi A, Alicante S, Dupuis-Girod S. The European rare disease network for HHT frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care. *European Journal of Medical Genetics* 2022; 65(1): Article 104370.

Bakker W, Dingenouts CKE, Lodder K, Wiesmeijer KC, de Jong A, Kurakula K, Mager H-JJ, Smits AM, de Vries MR, Quax PHA, Goumans MJTH. BMP Receptor Inhibition Enhances Tissue Repair in Endoglin Heterozygous Mice.. *International Journal of Molecular Sciences* 2021; 22(4): 2010.

Bofarid S, Hosman AE, Mager JJ, Snijder RJ, Post MC. Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology. *International Journal of Molecular Sciences* 2021; 22(7): 3471.

Galaris G, Montagne K, Thalgott JH, Goujon GJPE, van den Driesche S, Martin S, Mager H-JJ, Mummery CL, Rabelink TJ, Lebrin F. Thresholds of endoglin expression in endothelial cells explains vascular etiology in hereditary hemorrhagic telangiectasia type 1. *International Journal of Molecular Sciences* 2021; 22(16): Article Number 8948.

Kroon S, Snijder RJ, Hosman AE, Vorselaars VMM, Disch FJM, Post MC, Mager JJ. Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study.. *Angiogenesis* 2021; 24: 379–386.

Kroon S, van den Heuvel DAF, Vos JA, van Leersum M, van Strijen MJL, Post MC, Mager JJ, Snijder RJ. Idiopathic and hereditary haemorrhagic telangiectasia associated pulmonary arteriovenous malformations: comparison of clinical and radiographic characteristics.. *Clinical radiology* 2021; 76(5): 394.e1-394.e8.

Kroon S, van Thor MCJ, Vorselaars VMM, Hosman AE, Swaans MJ, Snijder RJ, Mager HJ, Post MC. The use of echo density to quantify pulmonary right-to-left shunt in transthoracic contrast echocardiography.. *European heart journal cardiovascular Imaging* 2021; 22(10): 1190–1196.

Bouma Marga J, Orlova Valeria, van den Hil Francijna E, Mager Hans-Jurgen, Baas Frank, de Knijff Peter, Mummery Christine L, Mikkers Harald, Freund Christian. Generation and genetic repair of 2 iPSC clones from a patient bearing a heterozygous c.1120del18 mutation in the ACVRL1 gene leading to Hereditary Hemorrhagic Telangiectasia (HHT) type 2. *Stem Cell Research* 2020; 46: 101786.

de Gussem EM, Kroon S, Hosman AE, Kelder JC, Post MC, Snijder RJ, Mager JJ. Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence.. *Journal of clinical medicine* 2020; 9(11): E3581.

de Jel DVC, Disch FJM, Kroon S, Mager JJ, Verdam FJ. Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia.. *Angiogenesis* 2020; 23: 271–274.

Eker Omer F, Boccardi Edoardo, Sure Ulrich, Patel Maneesh C, Alicante Saverio, Alsafi Ali, Coote Nicola, Droege Freya, Dupuis Olivier, Fialla Annette Dam, Jones Bryony, Kariholu Ujwal, Kjeldsen Anette D, Lefroy David, Lenato Gennaro M, Mager Hans Jurgen, Manfredi Guido, Nielsen Troels H, Pagella Fabio, Post Marco C, Rennie Catherine, Sabbà Carlo, Suppressa Patrizia, Toerring Pernille M, Ugolini Sara, Buscarini Elisabetta, Dupuis-Girod Sophie, Shovlin Claire L. European Reference Network

for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). *Orphanet Journal of Rare Diseases* 2020; 15(1): 165.

Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, Deslandres E, Kasthuri RS, Lausman A, Poetker D, Ratjen F, Chesnutt MS, Clancy M, Whitehead KJ, Al-Samkari H, Chakinala M, Conrad M, Cortes D, Crocione C, Darling J, de Gussem E, Derksen C, Dupuis-Girod S, Foy P, Geisthoff U, Gossage JR, Hammill A, Heimdal K, Henderson K, Iyer VN, Kjeldsen AD, Komiyama M, Korenblatt K, McDonald J, McMahon J, McWilliams J, Meek ME, Mei-Zahav M, Olitsky S, Palmer S, Pantalone R, Piccirillo JF, Plahn B, Porteous MEM, Post MC, Radovanovic I, Rochon PJ, Rodriguez-Lopez J, Sabba C, Serra M, Shovlin C, Sprecher D, White AJ, Winship I, Zarrabeitia R. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.. *Annals of internal medicine* 2020; 173(12): 989-1001.

Kroon S, Vorselaars VM, Hosman AE, Post MC, Snijder RJ, Mager JJ. Prevalence and diagnostic value of nail fold capillary microscopy in hereditary hemorrhagic telangiectasia: A retrospective study.. *Vascular medicine* 2020; 25(4): 341-347.

Mutize TT, Seedat RY, Ploos van Amstel JK, Mager JJ, Brown SC, Gebremariam F, Coetzee MJ. The clinical and genetic features of hereditary haemorrhagic telangiectasia (HHT) in central South Africa—three novel pathogenic variants.. *Molecular biology reports* 2020; 47: 9967–9972.

van den Heuvel DAF, Post MC, Koot W, Kelder JC, van Es HW, Snijder RJ, Vos JA, Mager JJ. Comparison of Contrast Enhanced Magnetic Resonance Angiography to Computed Tomography in Detecting Pulmonary Arteriovenous Malformations.. *Journal of clinical medicine* 2020; 9(11).

Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, Suppressa P, Zarrabeitia R, Dupuis-Girod S, Shovlin CL. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.. *Orphanet journal of rare diseases* 2019; 14(1): 28.

Kroon S, Snijder RJ, Mager JJ, Post MC, Tenthof van Noorden J, van Geenen EJM, Drenth JPH, Grooteman KV. Octreotide for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia: a prospective case series.. *American journal of hematology* 2019; 94(9): E247-E249.

Shovlin C L, Millar C M, Droege F, Kjeldsen A, Manfredi G, Suppressa P, Ugolini S, Coote N, Fiella A D, Geisthoff U, Lenato G M, Mager H J, Pagella F, Post M C, Sabbà C, Sure U, Torring P M, Dupuis-Girod S, E Buscarini E, VASCERN-HHT. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. *Orphanet Journal of Rare Diseases* 2019; 14(1): 210.

Andrejcsk JW, Hosman AE, Botella LM, Shovlin CL, Arthur HM, Dupuis-Girod S, Buscarini E, Hughes CCW, Lebrin F, Mummery CL, Post MC, Mager JJ. Executive summary of the 12th HHT international scientific conference. *Angiogenesis* 2018; 21(1): 169-181.

Kroon S, Snijder RJ, Faughnan ME, Mager HJ. Systematic screening in hereditary hemorrhagic telangiectasia: a review.. *Current opinion in pulmonary medicine* 2018; 24(3): 260-268.

Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, Geisthoff U, Ugolini S, Dupuis-Girod S. European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT).. *Orphanet journal of rare diseases* 2018; 13(1): 136.

Thalgott JH, Dos-Santos-Luis D, Hosman AE, Martin S, Lamandé N, Bracquart D, Srun S, Galaris G, de Boer HC, Tual-Chalot S, Kroon S, Arthur HM, Cao Y, Snijder RJ, Disch F, Mager JJ, Rabelink TJ, Mummery CL, Raymond K, Lebrin F. Decreased Expression of Vascular Endothelial Growth Factor

Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2. *Circulation* 2018; 138(23): 2698-2712.

Vorselaars VMM, Hosman AE, Westermann CJJ, Snijder RJ, Mager JJ, Goumans MJ, Post MC. Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia.. *International journal of molecular sciences* 2018; 19(10): 3203.

Vorselaars VMM, Velthuis S, Huitema MP, Hosman AE, Westermann CJJ, Snijder RJ, Mager JJ, Post MC. Reproducibility of right-to-left shunt quantification using transthoracic contrast echocardiography in hereditary haemorrhagic telangiectasia.. *Netherlands heart journal* 2018; 26(4): 203-209.

Hosman AE, de Gussem EM, Balemans WA, Gauthier A, Westermann CJ, Snijder RJ, Post MC, Mager JJ. Screening children for pulmonary arteriovenous malformations: Evaluation of 18 years of experience. *Pediatric Pulmonology* 2017; 52(9): 1206-1211.

Vorselaars V, Velthuis S, van Gent M, Westermann C, Snijder R, Mager J, Post M. Pulmonary Hypertension in a Large Cohort with Hereditary Hemorrhagic Telangiectasia. *Respiration* 2017; 94(3): 242-250.

Vorselaars VMM, Diederik A, Prabhudesai V, Velthuis S, Vos JA, Snijder RJ, Westermann CJJ, Mulder BJ, Ploos van Amstel JK, Mager JJ, Faughnan ME, Post MC. SMAD4 gene mutation increases the risk of aortic dilation in patients with hereditary haemorrhagic telangiectasia. *International Journal of Cardiology* 2017; 245: 114-118.

de Gussem EM, Edwards CP, Hosman AE, Westermann CJ, Snijder RJ, Faughnan ME, Mager JJ. Life expectancy of parents with Hereditary Haemorrhagic Telangiectasia. *Orphanet Journal of Rare Diseases* 2016; 11(1): 46.

Gkatzis K, Thalgott J, Dos-Santos-Luis D, Martin S, Lamande N, Carette MF, Disch F, Snijder RJ, Westermann CJ, Mager JJ, Oh SP, Miquerol L, Arthur HM, Mummery CL, Lebrin F. Interaction Between ALK1 Signaling and Connexin40 in the Development of Arteriovenous Malformations. *Arteriosclerosis, Thrombosis, & Vascular Biology* 2016; 36(4): 707-717.

Vorselaars VM, Velthuis S, Snijder RJ, Mager JJ, Post MC. Thoracic aorta dilation in patients with hereditary hemorrhagic telangiectasia due to SMAD4 gene mutation. *American Journal of Medical Genetics. Part A* 2016; 170(3): 811-812.

Vorselaars VM, Velthuis S, Snijder RJ, Westermann CJ, Vos JA, Mager JJ, Post MC. Follow-up of pulmonary right-to-left shunt in hereditary haemorrhagic telangiectasia. *European Respiratory Journal* 2016; 47(6): 1750-1757.

Hosman A, Westermann CJ, Snijder R, Disch F, Mummery CL, Mager JJ. Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia. *Rhinology* 2015; 53(4): 340-344.

Post MC, Mager JJ. Quality of life in pulmonary arterial hypertension. *Netherlands Heart Journal* 2015; 23(5): 275-277.

Velthuis S, Buscarini E, Gossage JR, Snijder RJ, Mager JJ, Post MC. Clinical Implications of Pulmonary Shunting on Saline Contrast Echocardiography. *Journal of the American Society of Echocardiography* 2015; 28(3): 255-263.

Velthuis S, Vorselaars VM, Westermann CJ, Snijder RJ, Mager JJ, Post MC. Pulmonary Shunt Fraction Measurement Compared to Contrast Echocardiography in Hereditary Haemorrhagic Telangiectasia Patients: Time to Abandon the 100% Oxygen Method. *Respiration* 2015; 89(2): 112-118.

Vorselaars VM, Velthuis S, Snijder RJ, Vos JA, Mager JJ, Post MC. Pulmonary hypertension in hereditary haemorrhagic telangiectasia. *World Journal of Cardiology* 2015; 7(5): 230-237.

Vorselaars VM, Velthuis S, Swaans MJ, Mager JJ, Snijder RJ, Rensing BJ, Boersma LV, Post MC. Percutaneous left atrial appendage closure-An alternative strategy for anticoagulation in atrial fibrillation and hereditary hemorrhagic telangiectasia?. *Cardiovascular Diagnosis & Therapy* 2015; 5(1): 49-53.

de Gussem EM, Lausman AY, Beder AJ, Edwards CP, Blanker MH, Terbrugge KG, Mager JJ, Faughnan ME. Outcomes of pregnancy in women with hereditary hemorrhagic telangiectasia. *Obstetrics & Gynecology* 2014; 123(3): 514-520.

Menko FH, Jacobs MA, Mager JJ, Nicolai JJ, Mensenkamp AR, Aalfs CM. Een jongeman met intestinale polyposis en epistaxis. *Nederlands Tijdschrift voor Geneeskunde* 2014; 158: A7398.

Velthuis S, Buscarini E, Mager JJ, Vorselaars VMM, van Gent MWF, Gazzaniga P, Manfredi G, Danesino C, Diederik AL, Vos JA, Gandolfi S, Snijder RJ, Westermann CJ, Post MC. Predicting the size of pulmonary arteriovenous malformations on chest computed tomography: a role for transthoracic contrast echocardiography. *European Respiratory Journal* 2014; 44(1): 150-159.

Vorselaars VMM, Velthuis S, Mager JJ, Snijder RJ, Bos W-, Vos JA, Strijen MJL, Post MC. Direct haemodynamic effects of pulmonary arteriovenous malformation embolisation. *Netherlands Heart Journal* 2014; 22(45876): 328-333.

van Gent MWF, Velthuis S, Post MC, Snijder RJ, Westermann CJ, Letteboer TGW, Mager JJ. Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria?. *American Journal of Medical Genetics Part A* 2013; 161(3): 461-466.

Velthuis S, Buscarini E, van Gent MW, Gazzaniga P, Manfredi G, Danesino C, Schonewille WJ, Westermann CJ, Snijder RJ, Mager JJ, Post MC. Grade of pulmonary right-to-left shunt on contrast echocardiography and cerebral complications; a striking association. *Chest* 2013; 144(2): 542-548.

Velthuis S, Vorselaars VM, van Gent MW, Westermann CJ, Snijder RJ, Mager JJ, Post MC. Role of transthoracic contrast echocardiography in the clinical diagnosis of hereditary hemorrhagic telangiectasia. *Chest* 2013; 144(6): 1876-1882.

Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. *Journal of Medical Genetics* 2011; 48(2): 73-87.

van Gent MW, Mager JJ, Snijder RJ, Westermann CJ, Plokker HW, Schonewille WJ, Thijs V, Post MC. Relation between migraine and size of echocardiographic intrapulmonary right-to-left shunt. *American Journal of Cardiology* 2011; 107(9): 1399-1404.

Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Breant C, Mathivet T, Larrivee B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL.

Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. *Nature medicine* 2010; 16(4): 420-428.

Post S, Smits AM, van den Broek AJ, Sluijter JP, Hoefler IE, Janssen BJ, Snijder RJ, Mager JJ, Pasterkamp G, Mummery CL, Doevendans PA, Goumans MJ. Impaired recruitment of HHT-1 mononuclear cells to the ischemic heart is due to an altered CXCR4/CD26 balance. *Cardiovascular Research* 2010; 85(3): 494-502.

van Gent MW, Post MC, Snijder RJ, Westermann CJ, Plokker HW, Mager JJ. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. *Chest* 2010; 138(4): 833-839.

de Gussem EM, Snijder RJ, Disch FJ, Zanen P, Westermann CJ, Mager JJ. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. *Rhinology* 2009; 47(1): 85-88.

Post MC, van Gent MW, Plokker HW, Westermann CJ, Kelder JC, Mager JJ, Overtoom TT, Schonewille WJ, Thijs V, Snijder RJ. Pulmonary arteriovenous malformations associated with migraine with aura. *European Respiratory Journal* 2009; 34(4): 882-887.

van Gent MW, Post MC, Luermans JG, Snijder RJ, Westermann CJ, Plokker HW, Overtoom TT, Mager JJ. Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: a prospective study. *European Respiratory Journal* 2009; 33(1): 85-91.

van Gent MWF, Post MC, Snijder RJ, Swaans MJ, Plokker HWM, Westermann CJJ, Overtoom TT, Mager JJ. Grading of Pulmonary Right-To-Left Shunt With Transthoracic Contrast Echocardiography: Does It Predict the Indication for Embolotherapy?. *Chest* 2009; 135(5): 1288-1292.

Westermann CJJ, Mager JJ, Mauser HW, Overtoom TTC. Stroke following pulmonary arteriovenous fistula embolization in a patient with HHT. *Neurology* 2009; 73(17): 1427.

Letteboer TG, Mager JJ, Snijder RJ, Lindhout D, Ploos van Amstel HK, Zanen P, Westermann KJ. Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. *American Journal of Medical Genetics. Part A* 2008; 164A(21): 2733-2739.

Post MC, van Gent MWF, Snijder RJ, Mager JJ, Schonewille WJ, Plokker HWM, Westermann CJJ. Pulmonary Arteriovenous Malformations and Migraine: A New Vision. *Respiration* 2008; 76(2): 228-233.

Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK, Westermann CJ. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. *Journal of Medical Genetics* 2006; 43(4): 371-377.

van Laake LW, van den Driesche S, Post S, Feijen A, Jansen MA, Driessens MH, Mager JJ, Snijder RJ, Westermann CJ, Doevendans PA, van Echteld CJ, ten Dijke P, Arthur HM, Goumans MJ, Lebrin F, Mummery CL. Endoglin has a crucial role in blood cell-mediated vascular repair. *Circulation* 2006; 114(21): 2288-2297.

Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, Lindhout D, Hennekam FA, Westermann CJ, Ploos van Amstel JK. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. *Human Genetics* 2005; 116(45689): 42583.

Post MC, Letteboer TG, Mager JJ, Plokker TH, Kelder JC, Westermann CJ. A Pulmonary Right-to-Left Shunt in Patients With Hereditary Hemorrhagic Telangiectasia Is Associated With an Increased Prevalence of Migraine. *Chest* 2005; 128(4): 2485-2489.

Mager JJ, Overtoom TT, Blauw H, Lammers JW, Westermann CJ. Embolotherapy of pulmonary arteriovenous malformations: long-term results in 112 patients. *Journal of Vascular & Interventional Radiology* 2004; 15(5): 451-456.

Westermann CJ, Rosina AF, de Vries V, Mager JJ. Hoge prevalentie van de ziekte van Rendu-Osler-Weber in de Afro-Caribische bevolking van de Nederlandse Antillen. *Nederlands Tijdschrift voor Geneeskunde* 2003; 147(33): 1595-1600.

Mager JJ, Zanen P, Verzijlbergen F, Westermann CJ, Haitjema T, van Herk G, Lammers JW. Quantification of right-to-left shunt with (99m)Tc-labelled albumin macroaggregates and 100% oxygen in patients with hereditary haemorrhagic telangiectasia. *Clinical Science* 2002; 102(2): 127-134.

Mager HJ, Overtoom TT, Mauser HW, Westermann CJ. Early cerebral infarction after embolotherapy of a pulmonary arteriovenous malformation. *Journal of Vascular & Interventional Radiology* 2001; 12(1): 122-123.

Mager JJ, Schutgens RE, Haas FJ, Westermann CJ, Biesma DH. The early course of D-dimer concentration following pulmonary artery embolisation. *Thrombosis & Haemostasis* 2001; 86(6): 1578-1579.

Mager JJ, Westermann CJ. Value of capillary microscopy in the diagnosis of hereditary hemorrhagic telangiectasia. *Archives of Dermatology* 2000; 136(6): 732-734.

Westermann CJ, Mager JJ. Osler-Rendu-Weber disease with liver involvement. *Jbr-Btr: Organe de la Societe Royale Belge de Radiologie* 2000; 83(2): 73.

Willemse RB, Mager JJ, Westermann CJ, Overtoom TT, Mauser H, Wolbers JG. Bleeding risk of cerebrovascular malformations in hereditary hemorrhagic telangiectasia. *Journal of Neurosurgery* 2000; 92(5): 779-784.

Mager JJ, Mauser HW, Westermann CJ. Intracraniele arterioveneuze malformatie bij zwangere vrouwen. *Nederlands Tijdschrift voor Geneeskunde* 1999; 143(21): 1116.